FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly, the use of human lactoferrin apo-form as an antihypoxant and a hypoxia inducible factor-1 alpha stabiliser.
EFFECT: invention provides the use of the natural iron chelator lactoferrin, no toxicity, hypoallergenicity, an ability to penetrate through the bowel into the blood flow and through the blood-brain barrier.
2 tbl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREVENTING HYPOXIA | 2003 |
|
RU2251432C2 |
| 3-(N,N-DIMETHYLCARBAMOYLHYDROXY)-2-ETHYL-6-METHYLPYRIDINE SUCCINATE SHOWING ANTIHYPOXIC ACTIVITY | 1993 |
|
RU2095350C1 |
| METHOD FOR INCREASING BODY RESISTANCE TO ACUTE HYPOXIA IN EXPERIMENT | 2013 |
|
RU2517032C1 |
| METHOD OF PRODUCING LACTOFERRIN | 2018 |
|
RU2717340C1 |
| PREPARATIONS OF ANTIHYPOXIC PROPERTIES | 2002 |
|
RU2232576C2 |
| ANTIHYPOXIC AGENT | 2001 |
|
RU2213571C2 |
| METHOD OF ADAPTATION OF ANIMAL BODY TO CHRONIC HYPOBARIC HYPOXIA IN EXPERIMENT | 2022 |
|
RU2800891C1 |
| AGENT FOR TREATING BODY IRON OVERLOAD, OR HAEMOCHROMATOSIS | 2014 |
|
RU2557959C1 |
| ANTIHYPOXIC AGENT | 2011 |
|
RU2472503C1 |
| METHOD FOR TREATING POSTOPERATIVE COMPLICATIONS | 2001 |
|
RU2199337C1 |
Authors
Dates
2012-10-27—Published
2011-03-11—Filed